{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.6193","value":"36.706"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"56"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.9473","value":"37.731"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"48"}],"units":"Participants"}],"title":"Day 29"}],"denoms":[{"counts":[{"groupId":"OG000","value":"56"}],"units":"Participants"}],"description":"* Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire.\n* The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures.\n* All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL.\n* Symptom scale/item higher score represents a high level of symptomatic problem.","dispersionType":"Standard Deviation","groups":[{"description":"Participants underwent leukapheresis and may receive salvage low- dose chemotherapy or one cycle of non-curative standard of care antitumor therapy if required. Eligible participants then received lymphodepleting chemotherapy with fludarabine and cyclophosphamide (flu/cy) followed by a single dose of JCAR017 (100×10\\^6 CAR+ T cells) administered intravenously (IV) 2 to 7 days after completion of lymphodepleting chemotherapy.","id":"OG000","title":"Lisocabtagene Maraleucel (JCAR017)"}],"paramType":"MEAN","populationDescription":"All participants who received at least one JCAR017 infusion who has an analyzable baseline scale and at least one post-baseline analyzable scale","reportingStatus":"POSTED","timeFrame":"Baseline and Day 29","title":"Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Fatigue Subscale","type":"SECONDARY","unitOfMeasure":"Scores on a scale"}